- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 4.3 Exhibit 4.3 Description of Securities of Avenue Therapeutics, Inc.
- 10.19 Exhibit 10.19 Kranzler Baergic
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
- 97.1 Exhibit 97.1 Clawback Policy
- Download Excel data file
- View Excel data file
Exhibit 32.1
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Annual Report on Form 10-K for the period ended December 31, 2023 (the “Report”) filed with the Securities and Exchange Commission:
● | Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
● | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Alexandra MacLean, M.D. | |
Alexandra MacLean, M.D. | |
Chief Executive Officer | |
(Principal Executive Officer) | |